Document Detail

The results of animal studies with ciprofibrate, a new orally effective hypolipidemic drug.
MedLine Citation:
PMID:  454514     Owner:  NLM     Status:  MEDLINE    
Findings are given to show that ciprofibrate, a new orally active phenoxyisobutyrate, is significantly more hypolipidemic than is the reference clofibrate. In hyperlipidemic rats ciprofibrate suppresses the increase in blood lipids 33% at a daily dosage of 0.6--3 mg/kg. The corresponding dosage for clofibrate is 125--460 mg/kg. Based on studies with cholesterol pools pre-labeled with [14C]mevalonate or with cholesterol-labeled pools in ciprofibrate-treated normolipidemic rats, ciprofibrate was shown to inhibit cholesterol biosynthesis. No evidence of the presence of 7- or 24-dehydrocholesterol was obtained in the sera of ciprofibrate-treated rats as shown by gas chromatography examination. The order of hypolipidemic effectiveness of ciprofibrate in hyperlipidemic rats provides a basis for anticipating that ciprofibrate will be hypolipidemic in hyperlipoproteinemic subjects who are considered at high risk of acquiring coronary artery disease.
A Arnold; J P McAuliff; L G Powers; D K Phillips; A L Beyler
Related Documents :
21194184 - A multiple-dose pharmacokinetics of polyethylene glycol recombinant human interleukin-6...
19323754 - Modulation of lipid metabolism by centella asiatica in oxidative stress rats.
9219904 - Cloning and in vitro expression of rat lecithin:cholesterol acyltransferase.
12236704 - Isoflavone-free soy protein prepared by column chromatography reduces plasma cholestero...
17113924 - The connexin 36 blockers quinine, quinidine and mefloquine inhibit cortical spreading d...
2216054 - Immunocytochemical localization of manganese superoxide dismutase (mn-sod) in the hippo...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Atherosclerosis     Volume:  32     ISSN:  0021-9150     ISO Abbreviation:  Atherosclerosis     Publication Date:  1979 Feb 
Date Detail:
Created Date:  1979-08-29     Completed Date:  1979-08-29     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0242543     Medline TA:  Atherosclerosis     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  155-63     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Anticholesteremic Agents / therapeutic use
Antilipemic Agents / administration & dosage,  therapeutic use*
Cholesterol / biosynthesis,  blood
Clofibrate / analogs & derivatives*,  therapeutic use
Cyclopropanes / therapeutic use
Drug Evaluation, Preclinical
Hyperlipidemias / drug therapy*
Triglycerides / antagonists & inhibitors,  blood
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Antilipemic Agents; 0/Cyclopropanes; 0/Triglycerides; 57-88-5/Cholesterol; 637-07-0/Clofibrate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Arterial entrance and metabolism of free and esterified plasma cholesterol measured in vivo in exper...
Next Document:  Geographic comparisons of diffuse intimal thickening of the aorta.